EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

Phase I study of [68Ga]Ga-HX01 for targeting integrin αvβ3 and CD13 in healthy and malignancy subjects

Xiao Zhang, Hanyi Fang, Biao Yang, Chunxia Qin, Fan Hu, Weiwei Ruan, Jing Chen, Dexing Zeng, Yongkang Gai, Xiaoli Lan iD

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-024-07002-3 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Xiao Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, 4…. Hauptthemen laut MEDLINE: Integrin alphaVbeta3, Neoplasms, Gallium Radioisotopes. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Hubei Provincial Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Integrin alphaVbeta3NeoplasmsGallium RadioisotopesHumansMaleFemaleMiddle AgedAdultTissue DistributionPositron Emission Tomography Computed TomographyAgedHealthy Volunteers

Stichwörter der Autor:innen

Dual-targetingMalignancyPETSafety[68Ga]Ga-HX01

Substanzen

Integrin alphaVbeta3Gallium Radioisotopes

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, 430022, Hubei, China.
  • Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022, Hubei, China.
  • Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, 430022, Wuhan, Hubei, China.
  • Hexin (Suzhou) Pharmaceutical Technology Co., Ltd, Taicang, 215421, Jiangsu, China.
  • Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, 430022, Hubei, China. gykmail@hust.edu.cn.
  • Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022, Hubei, China. gykmail@hust.edu.cn.

ORCID-Profile: Xiaoli Lan

Förderung

  • National Natural Science Foundation of China
  • Hubei Provincial Natural Science Foundation

Zitieren

APA

Zhang, X., Fang, H., Yang, B., Qin, C., Hu, F., Ruan, W., Chen, J., Zeng, D., Gai, Y., & Lan, X. (2025). Phase I study of [68Ga]Ga-HX01 for targeting integrin αvβ3 and CD13 in healthy and malignancy subjects. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-07002-3

Vancouver

Zhang X, Fang H, Yang B, Qin C, Hu F, Ruan W, et al. Phase I study of [68Ga]Ga-HX01 for targeting integrin αvβ3 and CD13 in healthy and malignancy subjects. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-024-07002-3

BibTeX
@article{Zhang2025,
  author = {Zhang, Xiao and Fang, Hanyi and Yang, Biao and Qin, Chunxia and Hu, Fan and Ruan, Weiwei and Chen, Jing and Zeng, Dexing and Gai, Yongkang and Lan, Xiaoli},
  title = {Phase I study of [68Ga]Ga-HX01 for targeting integrin αvβ3 and CD13 in healthy and malignancy subjects},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-024-07002-3}
}
Kostenlos starten →